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C L I N I C A L R E S E A R C H A R T I C L E
Effects of Conjugated Linoleic Acid and Metformin on
Insulin Sensitivity in Obese Children: Randomized
Clinical Trial
Nayely Garibay-Nieto,1,4 Gloria Queipo-Garcı́a,4 Flor Alvarez,1 Mayra Bustos,2
Erendira Villanueva,1 Fernando Ramı́rez,5 Mireya León,2 Estibalitz Laresgoiti-Servitje,6
Ravindranath Duggirala,7 Teresa Macı́as,4 Sergio Cuevas,4 Abel Jalife,3
Miguel Fonseca-Sánchez,4 Fabiola Serratos,2 and Juan Carlos López-Alvarenga7
1Children and Adolescent Obesity Clinic, 2Research Unit, and 3Department of Surgery, Hospital General de
México Eduardo Liceaga, 06726Mexico City, Mexico; 4Department of Human Genetics, Hospital General de
México Eduardo Liceaga–Facultad de Medicina, Universidad Nacional Autónoma de México, 04510 Mexico
City, Mexico; 5Specialized Center for Diabetes Control, Public Health Services, Mexico City, Mexico 11340;
6Basic Medical Sciences Department, TEC-ABC School of Medicine, Tecnológico de Monterrey, Mexico
05300; and 7School of Medicine, South Texas Diabetes and Obesity Institute, University of Texas Rio Grande
Valley, Edinburg, Texas 78539
Context: Insulin resistance precedes metabolic syndrome abnormalities and may promote car-
diovascular disease and type 2 diabetes in children with obesity. Results of lifestyle modification
programs have been discouraging, and the use of adjuvant strategies has been necessary.
Objective: This study aimed to evaluate the effects of metformin and conjugated linoleic acid (CLA)
on insulin sensitivity, measured via euglycemic-hyperinsulinemic clamp technique and insulin
pathway expression molecules in muscle biopsies of children with obesity.
Design: A randomized, double-blinded, placebo-controlled clinical trial was conducted.
Setting: Children with obesity were randomly assigned to receive metformin, CLA, or placebo.
Results: Intervention had a positive effect in all groups. For insulin sensitivity Rd value (mg/kg/min),
therewas a statistically significant difference between theCLA vs placebo (6.536 2.54 vs 5.056 1.46,
P = 0.035). Insulinemia and homeostatic model assessment of insulin resistance significantly im-
proved in the CLAgroup (P = 0.045). After analysis of covariancewas performed and the influence of
body mass index, age, Tanner stage, prescribed diet, and fitness achievement was controlled,
a clinically relevant effect size on insulin sensitivity remained evident in the CLA group (37%) and
exceeded lifestyle program benefits. Moreover, upregulated expression of the insulin receptor
substrate 2 was evident in muscle biopsies of the CLA group.
Conclusions: Improvementof insulin sensitivity,measured via euglycemic-hyperinsulinemic clampand
IRS2 upregulation, favored patients treated with CLA. (J Clin Endocrinol Metab 102: 132–140, 2017)
Obesity is a multifactorial disease with high preva-lence in Mexico. According to the 2012 National
Survey of Health and Nutrition, the prevalence of
overweight and obese children and adolescents in
Mexico is 34% (1). Insulin resistance has been recog-
nized as the main physiopathological event preceding
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metabolic syndrome abnormalities and may promote
cardiovascular disease and type 2 diabetes in individuals
with obesity (2). Lifestyle modification through healthy
food selection and consumption, a regular physical ac-
tivity program, and optimal sleep hygiene have been
proposed as the gold standard of care in these in-
dividuals. Unfortunately, the compliance and success of
these strategies are usually disappointing (3, 4), making
pharmacological approaches somewhat necessary.
Metformin (MET) is a biguanide used for the treatment
of type 2 diabetes in children and adolescents due to its
ability to decrease hepatic glucose production and increase
peripheral insulin sensitivity. MET has been proposed as
anadjuvant treatment in pediatric obesity efforts, especially
in the presence of insulin resistance and its comorbidities.
MET has beneficial effects on weight reduction and insulin
resistance in obese nondiabetic individuals (5, 6).
Conjugated linoleic acid (CLA) is a group of isomers of
linoleic acid, which are synthesized in the cud of ruminant
animals by fermentative bacteria (7). CLA is present in
dairy products, meat, and fat from beef and lamb. The
most common CLA isomer contained in these products is
cis-9,trans-11, which can be commercially synthesized
from linoleic acid–rich oils and prepared as a 50%
mixture with the trans-10,cis-12 isomer (8). Several
studies have acknowledged the beneficial effects of CLA
isomers on body composition (9, 10), immune response
(11), bacterial-induced colonic inflammation (12, 13), as
well as improvements in insulin sensitivity and lipid
metabolism in experimental animals and humans (9).
Additionally,CLApurportedly reduces fatty acid synthesis
in adipocytes, suggesting that this supplement decreases fat
deposition, directly contributing to an improvement in
body composition in adults and children (14). Nonethe-
less, the impact of CLA on human health and disease is still
controversial and research on this matter continues.
Based on the current obesity frequency inMexico, and
considering the limited and discouraging outcomes of
intervention programs, adjuvant strategies must be in-
stalled. The objective of the present study was to evaluate
the effects of MET and CLA on insulin sensitivity,
measured via the euglycemic-hyperinsulinemic clamp
technique (EHCT), in children with obesity.
Subjects and Methods
We performed a randomized, double-blinded, 16-week placebo
(PLB)-controlled trial in the Pediatric Obesity Clinic at the
Pediatrics Department of Hospital General de México (Mexico
City, Mexico).
Patients with obesity aged 8 to 18 years who had not been
previously intervened and had optimal psychological health
were included in the study. Obesity was defined using Cen-
ters for Disease Control and Prevention criteria [body mass
index (BMI) $ 95th percentile]. Exclusion criteria included
BMI$ 35 kg/m2, genetic or endocrine obesity, a systemic illness,
diabetes or prediabetes (according to American Diabetes As-
sociation criteria) (15), and the use of weight loss medications
that could modify lipids and glucose concentrations. The study
(no. DI/11/311/04/108) was approved by the hospital’s in-
stitutional review board; additionally, it was registered in
ClinicalTrials.gov (no. NCT02063802).
All participants were included in the standardized healthy
lifestyle program addressed to children and their parents. This
4-month program consisted of a monthly visit that included a
1-hour structured physical activity session (coordinated by a
physical trainer), followed by a psychoeducational group ses-
sion. The following information was presented to all partici-
pants: (a) description of a balanced and healthy nutrition, (b)
emotion-related eating behavior and family support, (c) the
benefits of physical activity, and (d) obesity-related comor-
bidities. These sessions were coordinated by nutritionists,
psychologists, pediatricians, pediatric endocrinologists, and a
physical trainer. Afterward, all patients held a medical con-
sultation to evaluate their anthropometry and medical condi-
tion, as well as their progression and acquisition of skills and
their compliance to the program. At the beginning of the
intervention a complete nutritional evaluation was performed
and a diet based on age, pubertal stage, and physical activity
requirements, according to the World Health Organization
and Food and Agricultural Organization guidelines, was
prescribed (16). The recommended diet composition was 55%
carbohydrates, 20% proteins, 25% lipids (,7% saturated fat,
,300 mg/d cholesterol, and ,1% trans fat), and ,3 g of salt
per day. Participants filled out a 24-hour nutritional recall
questionnaire during the 3 days prior to their follow-up ap-
pointment to assess diet compliance. All patients were en-
couraged to participate in sports activities at last 5 days a week
and for a minimum of 60 minutes.
To evaluate physical activity compliance, we tested fitness
achievement using the Harvard step test modified for the pe-
diatric population and a physical fitness score was calculated
(17); evaluations were applied at baseline and at the post-
intervention state. The overall intervention compliance was
evaluated through anthropometric, metabolic, and fitness pa-
rameter modifications, as well as through the acquisition of
healthy behavior knowledge.
Clinical trial design
This trial was conducted in accordance with the Declaration of
Helsinki and adhered to Good Clinical Practice Guidelines issued
by the International Conference of Harmonization. The children
and their parents providedwritten informedassent/consent. Eligible
patients were included in the lifestyle intervention program (LIP)
and randomized to receive eitherMET (1 g/d), CLA containing
50:50 isomers c9,t11 and t10,c12 (3 g/d), or PLB (1 g/d) 3 times a
day for 16 weeks. Visits were scheduled monthly. Diet, exercise,
and medication compliance, as well as anthropometric variables,
were recorded during each visit. The final evaluationwas similar to
baseline; EHCT and skeletal muscle biopsies were performed at the
postintervention state. Patients were eliminated when they showed
poor compliance tomedication (,80%or.100%) or intolerance,
or when $1 workshop sessions were missed.
Anthropometric and metabolic evaluation
Baseline evaluation consisted of complete anthropometric
and body composition analysis.Height andweightwere obtained
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with participants in light clothes and without shoes, using a
standardized stadiometer andmechanical scale. A 12-hour fasting
blood sample was drawn. Laboratory measurements included
glucose, lipid profile, and aminotransferases that were analyzed
enzymatically with the use of commercially available reagents.
Insulin was measured using Bio-Plex Pro human diabetes insulin
immunoassay by Bio-Rad (Hercules, CA). Fasting insulin resis-
tance and sensitivity surrogated indexes were calculated as
follows: homeostatic model assessment of insulin resistance
(HOMA-IR) = [fasting plasma insulin (mU/mL)3 fasting plasma
glucose (mmol/L)]/22.5, and quantitative insulin sensitivity check
index (QUICKI) = 1/[log fasting plasma insulin (mU/mL) +
log fasting plasma glucose (mg/dL)].
Clamp procedure
A 2-hour euglycemic-hyperinsulinemic clamp was per-
formed (18) and executed during a 12-hour fasting condition.
Intravenous catheters were inserted in the right and left forearm
vein, one in a retrograde direction, and warmed in a box that
was designed for this purpose (Kepis Keipis One Device, un-
published data). This device allowed the introduction of the
complete forearm and maintenance of adequate high temper-
ature and humidity that provided an arteriovenous shunt for
blood sample supply while avoiding burns. The additional vein
was used to infuse insulin and 20% dextrose solution at vari-
able rates. Intravenous crystalline insulin (Humulin; Eli Lilly &
Co., Indianapolis, IN) was used. A priming insulin dose of
120 mIU/m2 of body surface (bs) per minute at time 0 was admin-
istered after 1 hour of baseline and during the first 5 minutes.
Thereafter, the infusionwas gradually reduced to 60mIU/m2bs/min
up to minute 10 and maintained through the end of the clamp.
Glucose infusion started at minute 5 (5 mg/kg/min in all the
patients according to information obtained during the stan-
dardization procedure). The samples were obtained every
5 minutes, and glucose infusion was dynamically modified to
clamp plasma glucose at 85 to 95 mg/dL.
The rate of glucose disposal (Rd)was calculated and adjusted
during the last 30 minutes of the clamp when plasma glucose
stabilized at a fixed range.
Primary endpoints included the postintervention insulin
resistance state defined as the Rd value (mg/kg/min) measured
via EHCT, as well as the evaluation of surrogate indexes of
insulin resistance and sensitivity (insulinemia, HOMA-IR, and
QUICKI). The expression of insulin receptor substrates IRS1,
IRS2, and IRS4 in muscle biopsies complemented the insulin
resistance study. Secondary objectives were modifications of
anthropometric and metabolic parameters. Moreover, medi-
cation safety and tolerability were important outcomes.
Muscle biopsies
The participation of MET and CLA on the insulin signaling
pathway was explored with muscles biopsies from the vastus
lateralis performed under local anesthesia after 16 weeks of
intervention. An incision with a no. 11 surgical blade was made
to insert an 8 swg (4.0 mm) Bergstrom needle (Ultramed,
Milton, ON, CA).
RNA isolation
Total RNA was isolated from biopsies samples using an
RNeasy fibrous tissue minikit for muscle and an RNeasy lipid
tissue minikit for adipose tissue (Qiagen, Valencia, CA) fol-
lowing the manufacturer’s protocol. RNA concentration was
determined using a NanoDrop 1000 spectrophotometer
(Thermo Scientific, Waltham, MA). Integrity was evaluated by
agarose gel electrophoresis using a vertical chamber Enduro
(Labnet International, Edison, NJ) and the UltraSlim LED
Illuminator SLB-01 (Maestrogen, Las Vegas, NV).
Genetic expression of insulin receptors
The genetic expression patterns of IRS1, IRS2, and IRS4
were studied in 14 and 17 muscular tissue biopsies obtained
from the MET and CLA groups, respectively. Quantitative
reverse transcription polymerase chain reaction array (human
insulin signaling pathway, RT2 Profiler, PAHS-030Z, Qiagen)
was performed. Complementary DNA was prepared using an
RT2 polymerase chain reaction array first-strand kit (Qiagen)
according to the manufacturer’s instructions. Normalization
was computed with ACTB, B2M, GAPDH, HPRT1, and
RPLP0. The expression patterns observed in the MET and CLA
groups were compared with muscular tissue samples from the
PLB group (n = 17) used as calibrator. The differential gene
expression was calculated using the Qiagen software poly-
merase chain reaction analyzer through the 22DDCt analysis,
and a 2.5-fold change cut-off (P , 0.05) was considered.
Statistical analysis
Descriptive statistics for all numerical variables are reported
as the mean and standard deviation and standard error of the
mean (SEM) for contrasts as indicated in the text or figures.
Contrast among treatment groups was assessed by analysis of
variance and analysis of covariance (ANCOVA) for adjustment
by confounding variables. Post hoc analysis and the multiple
contrast hypothesis corrected by Fisher’s least significant dis-
tance were executed. The h2 effect sizes obtained from
ANCOVAs were transformed to Cohen’s d. x2 Analyses were
also executed to evaluate differences in proportion among
groups. SPSS software version 22 (IBM, Armonk, NY) was used
to conduct the statistical analyses. A probability of a error
of ,5% was considered as statistically significant.
Results
Participants and demographics
Enrollment occurred from August 2012 to July 2014.
One hundred ninety-eight individuals were potentially
eligible; 83 met inclusion criteria, signed consent and
assent forms, and were randomized to receive MET
(n = 24), PLB (n = 30), and CLA (n = 29). Fifty patients
completed the 16-week intervention; 1 external outlier
was identified and excluded during the analysis (PLB
group). In 1 case, EHCT performance was technically
impossible (CLA group). For this reason, we report the
results of 48 executed clamps (Fig. 1). Throughout the
study, 1 patient was eliminated when a preexisting li-
poma was surgically removed without notifying the re-
search team (PLB group); a second patient with
psychosocial anomalies and suspected pregnancy was
eliminated as well (PLB group). Twenty-nine patients
were eliminated due to poor medication compliance or
due to lack of interest (MET, n = 10; PLB, n = 10; and
CLA, n = 9). Pubertal development (Tanner stage 1,
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defined as prepubertal; Tanner stages 2 to 3, defined as
early puberty; and Tanner stages 4 to 5, defined as late
puberty) was assessed after a clinical inspection of the
mammary glands, testes volume, and pubic hair. De-
mographic and baseline characteristics were similar
among the groups (Table 1).
Anthropometric and metabolic results
No significant differences were observed in baseline
anthropometric and metabolic parameters or insulin
resistance measured by surrogate indexes of insulin re-
sistance (fasting insulinemia, HOMA-IR, and QUICKI).
Distribution of Tanner stage status did not differ among
the groups (x2 test, P = 0.415).
The overall impact of the intervention showed a positive
effect on weight, height, BMI, and waist circumference, as
well as on surrogated indexes of insulin resistance and
physical fitness score in all of the groups (Table 2). No
statistically significant differences were observed in these
parameters between treatment groups. No differences were
evident when comparing surrogate indices of insulin re-
sistanceduring the postinterventionphase among the groups.
Insulin sensitivity measured by EHCT
The primary outcome, insulin sensitivity, calculated
as the Rd value, showed significant difference between
the CLA group compared with PLB (6.53 6 2.54 vs
5.05 6 1.46, P = 0.035, Cohen’s d effect size of 74%)
(Table 3). Moreover, fasting insulinemia (Fig. 2) and
HOMA-IR (Fig. 3) significantly decreased in the CLA
group (P = 0.04). The adjusted analysis for controlling the
influence of modifying or confounding variables such as
BMI, change in BMI, age, Tanner stage, as well as dietary
and physical program compliance, over the Rd value,
showed that the Tanner stage had an independent ef-
fect over the Rd value (P, 0.001). When ANCOVAwas
executed and the aforementioned variables were con-
trolled, no statistically significant differences were found
between the three groups with regards to Rd value.
Nonetheless, a clinically relevant effect size remained evi-
dent when comparing the CLA and PLB groups (Cohen’s
d effect size of 37%), suggesting a decrease in insulin re-
sistance in patients receivingCLA. The effect size ofMET vs
PLBwas 10% (5.726 3.1 vs 5.386 3) and that ofMET vs
CLA was 20% (5.72 6 3.1 vs 6.34 6 2.8), favoring the
Figure 1. Flowchart representing the number of subjects at study enrollment and study termination. Fourteen clamp studies were conducted in
the PLB group, 17 in the MET-treated group, and 17 in the CLA-treated group.







/article/102/1/132/2804736 by guest on 06 O
ctober 2021
CLA-treated group. However, these effect sizes were not
clinically relevant.
We analyzed the changes between initial and final
serum triglycerides and high-density lipoprotein (HDL)
cholesterol by ANCOVA. For these particular variables,
no Tanner or change in BMI modified postintervention
levels. Furthermore, HDL cholesterol and triglyceride
baseline levels did show an influence over the final levels.
Lipid profile and adverse effects
Patients in the CLA group had a statistically significant
increase in serum triglycerides when comparedwithMET
(169.86 69 vs 113.16 27, P = 0.027), but not significant
when compared with PLB (P = 0.13). Moreover, HDL
levels were lower in the CLA group when compared with
MET (36.8 6 5.4 vs 44.86 6 8.7, P = 0.009), whereas
there were no differences when compared with PLB
(P = 0.26). The main differences favoringMET treatment
over the lipid profile were evident only when compared
with CLA.
Nonserious adverse events most commonly reported
were abdominal pain, diarrhea, dizziness, headache,
nausea, and gastritis. The frequency and severity of
symptoms were similar in the three groups (analysis of
variance, P = 0.314; x2 test, P = 0.28). Patients exhibiting
lack of compliance and/or dropout did not show a dif-
ference between groups. Additionally, a Little’s missing
completely at random analysis (P. 0.13) was conducted
to ensure that patient elimination was actually random
and homogeneous in all of the groups.
Muscle biopsies’ analyses
The analyses of IRS1, IRS2, and IRS4 revealed that
only IRS2 was modulated in the CLA group, showing
a 3.56-fold increase compared with the control group
(P = 0.043). The rest of the genes did not show statistically
Table 2. Overall Impact of Intervention Regarding Anthropometric, Metabolic, and Insulin Resistance
Outcomes in All Patients
Baseline (n = 48) 4 Months Postintervention (n = 48) P
Weight, kg 65.29 (2.2) 62.51 (2.15) ,0.001
Height, cm 150.2 (1.75) 151.7 (1.66) ,0.001
BMI, kg/m2 28.25 (0.45) 26.56 (0.51) ,0.001
Waist circumference, cm 87.9 (1.32) 83.8 (1.24) ,0.001
Glucose, mg/dL 87 (1.13) 85 (0.85) 0.28
Total cholesterol, mg/dL 167 (3.75) 161 (4.21) 0.07
HDL cholesterol, mg/dL 39.2 (1.27) 40.4 (1.21) 0.24
LDL cholesterol, mg/dL 105 (3.53) 100 (3.57) 0.056
Triglycerides, mg/dL 154 (9.96) 139 (9.73) 0.22
Insulin, mU/mL 40.9 (3.26) 34.5 (2.95) 0.025
HOMA-IR 8.86 (0.77) 7.27 (0.63) 0.018
QUICKI 0.64 (0.01) 0.68 (0.01) 0.014
Physical fitness score (Harvard test) 83.82 (7.96) 124.0 (5.44) ,0.001
The P values were determined by a paired-samples Student t test. Data are expressed as mean (SEM).
Abbreviation: LDL, low-density lipoprotein.
Table 1. Participant Characteristics at Randomization
MET (n = 14) Placebo (n = 17) CLA (n = 17) P
Age, y 11.43 (2.1) 12.59 (2.62) 11.41 (2.71) 0.31
Weight, kg 63.25 (12.6) 70.15 (13.11) 62.11 (18.47) 0.26
Height, cm 148.4 (10) 153.4 (12) 148.6 (13) 0.42
BMI, kg/m2 28.54 (2.8) 28.79 (2.8) 27.48 (3.7) 0.45
Waist circumference, cm 87.12 (7.6) 89.43 (8.45) 87.17 (11.2) 0.71
Glucose, mg/dL 87 (7) 87 (8.2) 85 (8.1) 0.62
Total cholesterol, mg/dL 167 (27) 167 (28) 162 (23) 0.79
HDL cholesterol, mg/dL 41 (10) 37 (8) 38 (8) 0.42
LDL cholesterol, mg/dL 107 (24) 106 (24) 100 (25) 0.67
Triglycerides, mg/dL 150 (62) 161 (60) 159 (84) 0.89
Physical fitness score (Harvard test) 81 (56) 83 (45) 85 (66) 0.98
Insulin, mU/mL 43.5 (22) 37.1 (17) 42.5 (27) 0.25
HOMA-IR 9.42 (4) 8.07 (4) 9.2 (6) 0.68
QUICKI-IS 0.63 (0.08) 0.64 (0.06) 0.66 (0.15) 0.54
Data are expressed as mean (standard deviation).
Abbreviation: LDL, low-density lipoprotein.
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significant differences. These data support the fact that
CLA has a critical effect in the molecular insulin pathway
through the upregulation of ISR2. This mechanismmight
be related to optimal glucose uptake observed in CLA-
treated patients.
Discussion
This study supports that CLA improves insulin sensi-
tivity, as measured by EHCT in a group of obese children,
and exceeds LIP benefits.
Because the prevalence of metabolic syndrome in our
pediatric clinic averages 35% and confers an 11-fold risk
of diabetes during early adult life (19), the exploration of
conventional and pharmacological strategies focusing on
improving the insulin sensitivity level is imperative. Re-
cent studies have revealed thatMET has important effects
on insulin sensitivity when compared with PLB, and its
use in nondiabetic, obese individuals has been massively
extended (6, 20, 21). A systematic review conducted by
Brufani et al. (6) revealed a significant but moderate
benefit of MET on weight reduction and fasting insulin
sensitivity compared with PLB or lifestyle interventions
alone. Nonetheless, when these outcomes were evaluated
by frequently sampled intravenous glucose tolerance test
(22) or hyperglycemic clamp technique (23), no signifi-
cant differences were reported. Wiegand et al. (5) dem-
onstrated in a randomized PLB-controlled trial a
beneficial effect ofMET on the insulin sensitivity index in
obese, insulin-resistant adolescents; however, no differ-
ences in body composition, weight, or BMI were found.
We found in our study a significant improvement in all
anthropometric parameters, including weight, BMI, waist
circumference, and body composition (fatmass and fat-free
mass, data not shown); nonetheless, these results were not
significantly different among the treatment groups. To our
knowledge, no randomized PLB-controlled trial using
EHCT had been executed for the evaluation of MET
benefits on insulin sensitivity in children. In the present
study, we found no differences on Rd value (mg/kg/min)
when comparing MET and PLB in the postintervention
period. These data could be consistent with the final results
of the Diabetes Prevention Program Research Group (24)
that showed that diabetes incidencewas better reduced in a
LIP group compared with PLB. Nonetheless, improvement
in terms of BMI, waist circumference, HDL cholesterol,
and triglycerides, with considerable effect sizes (72%,
65%, 37%, and 55%, respectively), favored patients
treated with MET in our study.
Several studies have proposed beneficial effects of CLA
isomers on body composition, inflammation, and insulin
sensitivity, promoting differentiation, lipid metabolism
regulation, and apoptotic mechanisms in adipocytes
(10–12). Interestingly, evidence has suggested that the
trans-10,cis-12 isomer of CLA might induce insulin re-
sistance, whereas the CLA mixture has beneficial effects
on body composition and insulin sensitivity. Risérus et al.
(25) demonstrated that trans-10,cis-12 isomer–treated
subjects presented insulin and glucose increases and de-
creased HDL and insulin sensitivity measured by 2-hour
EHCT compared with PLB or CLA mixture-treated
groups. No differences were observed when comparing
PLB and CLA mixture-treated individuals. In our study,
we showed that the CLA mixture was associated with a
clinically relevant effect size (37%) over the Rd value of
insulin sensitivity. The confounding variables included in
the ANCOVA model showed a decline on group dif-
ferences. Among these adjustments, Tanner stage was the
main variable that modified insulin sensitivity, and de-
spite our small sample size, the effect size of CLA on the
Rd value remained.
Despite the fact that several CLA isomers might have
deleterious effects on insulin sensitivity and resistance,
certain mixtures may neutralize negative effects and even
Table 3. Characteristics of Main Interest Variables After 4 Months of Intervention
MET (n = 14) Placebo (n = 17) CLA (n = 17) P
Weight, kg 60.85 (3.41) 66.48 (3.19) 59.91 (4.34) 0.39
Height, cm 149.89 (2.45) 154.82 (2.82) 150.27 (3.19) 0.40
BMI, kg/m2 26.17 (0.99) 27.53 (0.78) 25.92 (0.90) 0.37
Waist circumference, cm 82.31 (1.87) 84.96 (1.77) 83.92 (2.68) 0.70
Prescribed diet compliance, % 92.04 (6.15) 83.78 (6.21) 83.09 (3.56) 0.43
Physical fitness score (Harvard test) 103.82 (16) 132.9 (13.09) 132.79 (14.61) 0.29
Rd value, mg/kg/min 5.57 (0.47)a,b 5.05 (0.35)b 6.53 (0.61)a 0.035
Insulin, mU/mL 40.5 (6.37) 32.3 (4.11) 31.6 (5.05) 0.42
HOMA-IR 8.53 (1.36) 6.83 (0.88) 6.68 (1.08) 0.45
QUICKI-IS 0.65 (0.02) 0.69 (0.02) 0.71 (0.02) 0.38
HDL cholesterol 44.86 (2.33)a 40.00 (2.15)a,b 36.876 (1.35)b 0.031
Triglycerides, mg/dL 113.14 (7.26)b 134.12 (20.36)a,b 169.80 (15.93)a 0.027
Data are expressed as mean (SEM).
a,bHomogeneous groups by Fisher’s least significant difference contrast.
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induce a synergistic positive response on these parame-
ters, as well as on metabolic and anthropometric values.
Some effects of the trans-10,cis-12 isomer promote a
blunted glucose uptake that depends on decreased
expression of glucose transporter 4 (GLUT-4) (26).
Moreover, decreased incorporation of free fatty acids
into the cells may be induced by CLA, a mechanism that
could be related to diminished expression of peroxisome
proliferator-activated receptor-g in adipocytes (27). CLA
has been proposed as an apoptotic accelerator of adi-
pocytes inmammals that liberates and increases fatty acid
oxidation elsewhere in the body (28). Evidence of dele-
terious effects hasmainly been reported in animalmodels,
in which administered doses of CLA are superior to those
used in humans (0.2 to 3 g/kg vs 0.015 to 0.1 g/kg, re-
spectively) (29). These effects, if present in humans, could
be hyperglycemia and hyperlipidemia, which may pre-
dispose an individual to diabetes and nonalcoholic fatty
liver disease (30, 31). However, few studies have been
published regarding themolecular mechanisms of CLA in
skeletal muscle that could explain increased glucose
uptake in our treated patients. On this matter, Vaughan
et al. (32), using a rabdomyosarcoma cell line, have re-
ported that omega-3 fatty acids and CLA activate mi-
tochondrial proliferation and glycolytic activation
pathways probably by apoptosis induction and sub-
sequent upregulation of GLUT-4. Furthermore, animal
models have shown the beneficial effects of CLA on in-
sulin sensitivity and overexpression of peroxisome
proliferator-activated receptor-g and GLUT-4 in the
muscle of supplemented rats (27). In the present study we
were able to demonstrate that postintervention IRS2
expression in the skeletal muscle was significantly
upregulated in CLA-treated patients. To our knowledge,
no studies have been published regarding the effects of
CLA or CLA–isomer mixtures on insulin receptor sub-
strate molecules. Xu et al. (33) reported that MET
upregulates insulin receptor b expression and the
downstream IRS2/phosphatidylinositol 3-kinase/Akt
signaling transduction in an insulin-resistant rat model
of nonalcoholic steatohepatitis and cirrhosis. Our results
evidenced a nonsignificant but marginal (P = 0.055) IRS2
upregulation in MET-treated children. The insulin-
sensitizing effects of MET have been mainly described
in liver tissue. Although CLA effects have been mainly
focused on adipose tissue modeling, the present study
demonstrates that molecular mechanisms, particularly
IRS2 upregulation, might mediate insulin-sensitizing ef-
fects on skeletal muscle. This phenomenon could explain
the increased glucose infusion rate tolerability in our
patients treated with CLA throughout the EHCT.
Moreover, significant HOMA-IR improvement observed
only in CLA-treated patients denotes a significant per-
formance in skeletal muscle that promotes a lower
pancreatic insulin secretion.
A recently published meta-analysis demonstrated that
the deleterious effects of CLA consumption might be neg-
ligible, whereas its benefits, although subtle, seem to be
clinically relevant regarding weight and fat mass loss (34).
In our study, BMI improvement was significant in all
groups, although not significantly different among them.
Nonetheless, MET displayed the highest effects over BMI
(72%, compared with 43% in the PLB group and 41% in
Figure 3. HOMA-IR was significantly lower in the CLA-treated
group at study termination compared with initial values. No
differences were found in the MET-treated and control groups. The
error bars show SEM.
Figure 2. Fasting insulin serum concentrations were significantly
lower in the CLA-treated group at study termination, whereas no
differences were found in the MET-treated patients or in the PLB
group. The error bars show SEM.
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CLA-treated patients) and waist circumference (70%,
compared with 60% in PLB and 30% in the CLA group).
Total body fat did not improve in any group, but leptin
levels significantly decreased in all patients (P,0.014, data
not shown).
Racine et al. (10) reported a clinical trial in a pediatric
population randomly assigned to CLA (3 g/d, c9,t11-t10-
c12, 50:50) or PLB for 6 months that showed a decrease in
total body fat in the CLA group and a significant decrease
inHDL cholesterol levels in CLA-treated patients.Our trial
demonstrated a significant improvement in HDL choles-
terol levels in PLB-treated patients (baseline vs post-
intervention, P = 0.045). In the CLA group, we noticed a
decline in theHDL cholesterol concentration thatwas not
statistically significant when compared with PLB.
One of the limitations of this study was the high rate of
participants’withdrawal, as well as the difficulties related
to the EHCT, both of which contributed to the final small
number of participants, as we did not have enough power
for seizing small size effects associated with the treatment.
The strength of this study is supported by its own de-
sign. For example, inclusion and, particularly, elimination
criteria were strictly applied. Baseline characteristics of
participants were similar regarding anthropometric and
metabolic condition, particularly those related to sub-
rogated indexes of insulin resistance. Additionally, the
main outcome was evaluated by the gold standard EHCT,
and the benefits of the overall LIP were evident and
similar, regardless of treatment allocation. Although the
withdrawal of participants was high in our study, the
elimination was random and homogeneous in all groups.
Conclusions
The current study demonstrates the benefits of an LIP and
additional effect of CLA over the gold standard EHCT.
Lifestyle intervention, independent of any treatment,
showed effects on the main outcome variables, specifi-
cally weight, height, BMI, waist circumference, surrogate
indexes of insulin resistance, and fitness condition, in all
of the groups. IRS2 upregulation was evident in CLA-
treated patients; this mechanism might be involved in
insulin-sensitizing effects on skeletal muscle.
Finally, the incidence of hypertriglyceridemia and
hypo-a-lipoproteinemia in CLA-treated patients might
be a concern and may be related to the types of CLA
isomers used in this study. Further research to evaluate
the benefits of different mixtures of CLA isomers may be
warranted.
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